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GENETICALLY MODIFIED T-CELLS EXPRESSING 




Dr. Carl June and his colleagues at the University of Pennsylvania have succeeded in 
treating patients with Chronic Lymphocytic Leukemia using gene therapy. Two of the three 
patients treated sustained a complete remission and one a partial remission. The procedure 
involved transducing the patients’ T cells to express chimeric antigen receptors which target a 
particular protein found on both healthy and cancerous B cells. Following infusion of the 
newly transduced T cells, each patient developed clinical symptoms associated with an intense 
immune response. Shortly thereafter, tumors were completely eliminated in two of the patients 
and partially eliminated in the third. All three patients were pre-treated with conventional 
therapies and responded poorly. This study coalesces volumes of research in genetics, 
immunology, and molecular biology in what might just be the future of cancer treatment.  
INTRODUCTION 
Harnessing the body’s own immune system to battle cancer has always been 
understood by medical scientists as the ideal avenue for treatment. An astounding 
Phase-1 Clinical Trial recently conducted at the University of Pennsylvania (UP) may 
prove to be a breakthrough in this area. The study represents a culmination of twenty 
years of intense research in immunology and gene therapy. Dr. Carl June and his 
colleagues at UP treated three patients having advanced chemotherapy-resistant CLL 
(chronic lymphocytic leukemia), a cancer of B-Cells. The trial involved transducing 
the patients’ own T-cells to express chimeric antigen receptors, a fairly recent 
biomolecular invention, generally referred to as CARs (June et al. 2011). CARs, 
genetically engineered receptors, are generally comprised of a constant region that is 
similar to that of any T-cell receptor and a variable region that targets a specific 
antigen (Eshhar et al. 1989). With the correct genetic engineering and biomolecular 
construction, T-cells can be induced to express CARs that target a gamut of antigens. 
In the trial led by Dr. June, the patients’ T-cells were transduced via an HIV-1 based 
lentiviral vector to express a CAR with specificity for CD19 (cluster of differentiation 
19), a protein found on both healthy and cancerous B-cells. The modified cells are 
referred to as CART19 (chimeric antigen receptor T 19) cells.  
Following exogenous transduction, the patients’ T-cells were infused 
intravenously. Within one to three weeks, all three patients developed symptoms that 
were indicative of a serious immune response. The CAR T-cells expanded in vivo at 
least a thousand fold and successfully eliminated both healthy and cancerous B-cells. 
The effector-to-target (E/T) ratios observed in the patients were 1: 93,000; 1:2,200; 
and 1:1,000. Hence, in the patient with an E/T ratio of 1:93,000, an infusion of 1.4 x 
1011 CART19 cells resulted in the remarkable elimination of 1.3 x 1012 CLL cells.  Two 
of the three patients sustained complete remission, and one patient experienced a 
partial remission. Furthermore, in the two patients achieving complete remission, a 
population of memory CART19 cells was observed months after treatment, indicating 
the possibility of prolonged immuno-surveillance (June et al. 2011).  
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CHIMERIC ANTIGEN RECEPTORS  
The original construct of T-cells expressing chimeric antigen receptors was 
designed two decades ago by Dr. Zelig Eshhar and his colleagues at the Weizmann 
Institute of Science (Bridgeman et al. 2010). Their CAR T-cell was transduced with 
rearranged gene segments coding for the variable domain (VH and VL chains) of an 
anti-trinitrophenyl antibody attached to constant region (either alpha or beta) of a T-
cell receptor. The transmembrane and cytoplasmic domains of a typical T-cell receptor 
were maintained. The resulting T-cells then produced an efficient immune response 
when exposed to trinitrophenyl. In response to the hapten, the CAR T-cells 
proliferated, produced interleukin 2, and targeted cell lysis (Eshhar et al. 1989).  
The fact that T-cells can be endowed with antibody-type specificity is highly 
significant. Typically, T-cells only respond to an antigen that is bound to MHC (major 
histocompatibility) protein, either I or II. When antigen-presenting cells, such as 
macrophages; B cells; and dendritic cells, encounter an antigen, they process it. The 
procedure involves ingesting the foreign molecule, synthesizing an MHC molecule, 
fusing the two, and attaching this antigen-MHC complex to the plasma membrane of 
the cell. T-cells only respond to an antigen presented in this way. More specifically, 
CD4 cells react to antigens bound to MHC-II molecules, and CD8 cells respond to 
antigens that are bound to MHC-I molecules. The necessity of having an antigen 
bound to an MHC molecule in order to elicit an immune response in T-cells is known 
as MHC restriction (Tortora and Derrickson 2009). 
MHC restriction can be circumvented with CARs. Since the CAR has the 
variable region of an antibody, it acts as one. Antibodies react with antigens in their 
native state to elicit an immune response. Thus, CARs can be used to target antigens 
that would normally not be presented with an MHC molecule (Eshhar et al. 1989), 
such as in the UP trial where the CARs targeted the CD19 protein found on B cells. In 
addition, in situations where MHC-I may be somewhat down-regulated by tumors as 
part of a strategy to inhibit immuno-surveillance, the use of CARs in the treatment of 
cancer may be more favorable (Bridgeman et al. 2010).  
T-Cell activation usually requires two signals. One is delivered by the TCR-
CD3 complex which interacts with the MHC-antigen complex. The other is delivered 
by co-stimulatory domain CD28 when it interacts with the co-stimulatory molecules 
(such as CD80 or CD86) found on the antigen presenting cells. Other co-stimulatory 
domains, such as CD137 or CD134 may also be necessary.  
The optimal construction of CARs has been explored during the past two 
decades (Eshhar et al. 2001).  Naturally, the precise design would depend on the 
target antigen and efficacy of the CAR. As illustrated in Figure 1, first generation 
CARs consist of the single-chain variable fragment (scFv) of an immunoglobulin 
specific for antigen (usually a tumor antigen), bound to a hinge region that crosses the 
cell membrane. The hinge region is attached only to the CD3- ! chain of the TCR-CD3 
complex which plunges into the cytoplasm and acts as the signaling domain.  
To enhance effectiveness, second generation CARs have a co-stimulatory 
signaling domain, such as CD28, CD137 (4-1 BB), or OX40, inserted between the 
hinge region and the CD3- ! chain (Urba and Longo 2011). For example, inclusion of 
a CD137 co-stimulatory signaling domain significantly enhanced in vivo persistence of 
CARs and antitumor activity in preclinical trials (Kalos et al. 2011, as described in 
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June et al. 2009). Third generation CARs incorporate various combinations of co-
stimulatory domains (Urba and Longo 2011).  
!
Figure 1: T-Cell Activation.  
“Optimal T-cell activation requires a minimum of two signals. Signal 1 is delivered by the TCR–CD3 
complex through interaction of the T-cell receptor (TCR) alpha and beta chains as they recognize 
peptide presented by a class I (CD8 T cells) or class II (CD4 T cells) major histocompatibility 
complex (MHC) molecule. Signal 2 is most commonly provided by the engagement of CD28 on the 
T cell with the costimulatory molecule CD80 or CD86 on the antigen-presenting cell. CD137 (4-
1BB) and CD134 (OX40) also provide costimulation to T cells. The optimal combination of effector 
function, proliferation, and survival requires both signals. Delivery of signal 1 without costimulation, 
which often occurs for tumor-infiltrating lymphocytes and transgenic T cells encountering antigen 
on a solid tumor devoid of costimulatory molecules, leads to anergy and apoptosis, thereby limiting 
the antitumor response. The first-generation chimeric antigen receptors usually comprise of a single-
chain variable fragment of an antibody specific for tumor antigen, linked to the transmembrane and 
intracellular signaling domain of CD3-zeta. Second-generation chimeric antigen receptors were 
developed to incorporate the signaling domain of a costimulatory molecule to improve T-cell 
activation and expansion. Third-generation chimeric antigen receptors include combinations of 
costimulatory domains.” (Data are from Keith Bahjat, Ph.D.) Source: Urba and Longo 2011 
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Currently, expression of CARs on non T-cells is limited due to difficulties in 
transfection, although developments are underway. Furthermore, CARs only target 
molecules expressed on cell surfaces. Thus, intracellular tumor specific antigens would 
require a different approach (Bridgeman et al. 2010).  
HIV-1 BASED LENTIVIRAL VECTORS 
A key factor in effectively transducing T-cells, as in any other aspect of gene 
therapy, is choice of the vector. Safety; long-term stability; versatility; and, sometimes, 
the ability to transduce non-dividing cells are all taken into account (Lu et al. 2004). In 
the UP trial, an HIV-1 based lentiviral vector was used. Lentiviruses (lenti is the Latin 
word for “slow”) are thus named because of the long incubation period between 
infection and the onset of disease. What makes lentiviruses unique among retroviruses 
is their ability to infect non-dividing cells (Durand and Cimarelli 2011). Typically, a 
retrovirus must wait until the S phase of the cell cycle when it is afforded the 
opportunity of penetrating the nuclear membrane. Thus, it cannot infect the cell unless 
the cell is dividing. However, lentiviruses have the ability to integrate into the host’s 
genome by penetrating the nuclear membrane on their own (Lu et al. 2004). This 
makes them highly useful in gene therapy whose main targets include the brain, lungs, 
liver, muscles, and hematopoietic system (Zufferey et al. 1998). In addition, 
transcriptional silencing has been observed in the use of onco-retroviral vectors and 
not in the use of lentiviral vectors. In fact, lentiviral vectors have successfully 
integrated into a variety of tissues (Vigna and Naldini 2000). Furthermore, these 
vectors are capable of carrying large transgenes of up to 18,000 bases (Coleman et al. 
2003). One drawback of lentiviral vectors is that they integrate into the host’s genome 
at random locations. Sometimes, this may activate nearby oncogenes. A number of 
patients in a clinical trial undergoing gene therapy for SCID – "C (severe combined 
immunodeficiency) syndrome developed leukemia as a result of the use of lentiviruses 
(Durand and Cimarelli 2011). Only one virus is known to incorporate itself at a 
specific site in the human genome—the adeno-associated virus that partially integrates 
into the human chromosome 19q13.42. Scientists are attempting to find a way to 
transpose the site-specificity of the adeno-associated virus to lentiviruses (Durand and 
Cimarelli 2011).      
HIV STRUCTURE 
The HIV virus (Figure 
2) contains two copies of a 
single-stranded RNA 
measuring 9,749 nucleotides 
long enclosed in a capsid. 
Bound to the RNA are 
nucleocapsid proteins p6 and 
p7 (which prevent the RNA 
from digestion by nucleases) 
and enzymes such as reverse 
transcriptase and integrase. 
These enzymes allow the virus 
to transcribe DNA off its 
RNA and then integrate into Figure 2: HIV Structure. Source: Henderson C. 
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the host’s genetic material, respectively (Kuiken et al. 2008). Along the viral envelope 
are protein units that aid in attachment to the host cell. Each unit consists of three 
transmembrane subunits of glycoprotein 41 attached to three external subunits of 
glycoprotein 120 (Chan et al. 1997). Surrounding the capsid and anchoring these 
glycoproteins into the envelope is a matrix composed of the protein p17 (Kuiken et al. 
2008).  
HIV GENOME 
The typical HIV genome contains nine genes flanked by LTRs (long terminal 
repeats). The gag, pol, and env genes code for viral structural proteins. Gag codes for a 
p17 presursor, capsid protein p24, necleocapsid proteins p6 and p7, and spacer 
peptides. Pol codes for HIV protease, integrase, and reverse transcriptase. The env 
(envelope) gene codes for glycoprotein 160, a precursor to gp41 and gp 120 which are 
necessary for viral attachment to the host cell (Watts et al. 2009). 
Tat and rev are two regulatory genes. Tat activates expression of the viral RNA, 
and rev promotes cytoplasmic export of gag, pol, and env transcripts. Vif, nef, vpu, and vpr 
are accessory genes critical for 
pathogenesis but not for 
replication (Vigna and Naldini 
2000). 
CONSTRUCTION OF 
SAFE HIV-1 BASED 
VECTORS  
Constructing safe 
vectors presents many 
challenges. The virus must 
retain those genes necessary 
for efficient transduction of 
target cells. At the same time, 
genes that would enable the 
virus to reproduce and infect 
other cells following 
transduction must be 
eliminated.    
Effective transduction 
using the two-plasmid 
production approach involves 
the introduction of two 
genomic constructs into the 
target cell: a transfer vector 
construct (Figure 3) and a 
packaging construct, also 
known as the helper plasmid 
(Figure 4). The transfer vector 
construct contains cis- acting 
sequences that are vital for the 
transfer and integration of the 
Figure 3: Various HIV-1 derived transfer vector constructs. 
Source: Vigna and Naldini 2000 
 
Figure 4: Various HIV-1 derived packaging 
constructs/helper plasmids. Source: Vigna and Naldini 2000 
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viral genome into a host’s genome. The transgene is hooked onto the transfer vector 
construct. The packaging construct contains trans-acting genes that code for the 
essential viral proteins. When both constructs are introduced into the same cell, they 
express proteins necessary for encapsulation and integration of the transfer vector. As 
these vectors are carefully engineered to adhere to the highest standards of biosafety, 
this infectious process happens only once. This is due to efficient removal of genetic 
material that would enable the virus to proliferate and infect other cells.   
In first generation HIV-1 derived packaging constructs, all genes necessary for 
the production of structural and accessory proteins are maintained; only env is 
eliminated. In second-generation constructs, the accessory genes, vif, nef, vpu, and vpr 
are also absent. In the third generation, tat and rev are eliminated as well, although rev 
is expressed by a separate construct that is flanked by a rous sarcoma virus promoter 
and a polyadenylation signal. Thus, only three out of the original nine genes are 
expressed.  
Transfer vectors house the transgene as well as GA and RRE, which are placed 
adjacently between an LTR and the internal promoter. GA is a derivative of the gag 
gene, while RRE (rev-responsive element) is a portion of the env gene (Vigna and 
Naldini 2000). 
Elimination of most viral genes is necessary in order to avoid RCR (replication 
competent recombinants), which can happen if the trans-acting viral genes in the 
packaging constructs merge with the cis-acting sequences in the transfer vector. In 
fact, the biosafety of a vector depends on the extent of successful separation between 
the functions of the cis-acting and trans-acting viral genomes that comprise the transfer 
vector construct and packaging construct, respectively.  
To avoid the emergence of RCR, self-inactivating (SIN) transfer vectors have 
been designed. In a wild-type LTR transfer vector (non-SIN), the LTRs are 
maintained. In the SIN transfer vector, there is a large deletion in the U3 region of the 
3’ LTR. Upon transduction, this deletion is duplicated upstream, resulting in 
inactivation of both LTRs (Vigna and Naldini 2000). Thus, during reverse 
transcription, the deletion is transferred to the proviral DNA, resulting in ineffective 
transcription of the LTRs. This avoids the hazardous production of complete vector 
RNA, since the LTRs contain promoter and enhancer sequences. In addition, sabotage 
of the LTRs prevents aberrant expression of sequences in the host’s genome that are 
adjacent to the vector integration site. Transcription of the transgene is, instead, driven 
by an internal promoter that is nestled safely away from the cell’s native genome 
(Zufferey et al. 1998). 
The improved SIN transfer vector has some additional constituents. The 
central polypurine tract (cPPT) sequence (which provides increased transduction 
efficiency and transgene expression) of the pol gene is inserted just before the internal 
promoter in order to improve gene transfer performance. The post-transcriptional 
regulatory element of the woodchuck hepatitis virus (Wpre), which improves the 
performance of vectors, is inserted just after the transgene to enhance its expression 
(Vigna and Naldini 2000).!  
Lentiviral vectors, as observed by stable expression of marker genes in vivo, can 
successfully transduce a spectrum of cells. Neurons of adult rat brains were the first 
cells in which stable expression of lentiviral tranduction was observed (Vigna and 
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Naldini 2000, as described in Verma et al. 1996). Other cells that have been 
successfully transduced with lentiviral vectors include cells of the retina, liver cells of 
rodents (Miyoshi et al. 1997), human dendritic cells and  macrophages (Schroers et al. 
2000), and human CD34+ and CD38- hematopoietic cells (Case et al. 1999).  
FIRST LENTIVIRAL VECTOR EVALUATED IN HUMAN CELLS, 
VRX494 and its sister VRX496 were the first lentiviral vectors to be evaluated 
in human cells. The trial was conducted by Xiaobin Lu and his colleagues at the 
Sydney Kimmel Comprehensive Cancer Center of the John Hopkins School of 
Medicine. The HIV env gene is not eliminated from VRX494 and 496; instead, these 
vectors express a 937-base antisense to silence the gene. VRX496 contains a 186-base 
sequence that acts as a molecular marker and is derived from the Green Fluorescence 
Protein (GFP) gene. VRX494 has an enhanced GFP gene.  
The cells transduced in this experiment were human CD4+ T lymphocytes. 
Human blood was obtained, and CD4+ cells were isolated with the magnetic activated 
cell-sorting system. Flow cytometry indicated a purity >95%. The cells were then 
cultured in X-vivo 15 media containing 10% human serum and the antibiotic 
gentamycin. In preparation for transduction, the cells were plated in a 24-well plate at 
1 x 106 cells per well.  VRX494 was added to the cells at 20 tranducing units per cell. 
Concurrently, to ensure activation and expansion of the cells, immobilized anti-
CD3/CD28 (iCD3/28) antibodies were added at a ratio of three beads per cell as well 
as 100 U/ml of interleukin 2. The cells were then cultured for three days during which 
they were washed three times to remove the vector. The iCD3/28 beads were removed 
four days later. Finally, the lymphocytes were replated at half a million cells per ml. At 
this point, the culture was able to be maintained for a significant amount of time.  
After seven days in culture, the tranduced cells were assessed for GFP 
expression which would indicate successful integration. Flow cytometry indicated that 
99.4% of tranduced cells were positive for vector gene expression, while 99.9% of the 
control cells were negative.  
To measure stability of transduction, another batch of CD4+ T lymphocytes 
were transduced at 20 TU/cell as well. The cells were allowed to expand 1.5-million-
fold over 36 days during which GFP expression was monitored.  GFP expression 
remained stable throughout the entire culture period, demonstrating consistent vector 
payload expression. To date, no RCR generation has been reported in the use of 
VRX494 and VRX496 (Lu et al. 2004).  
CHIMERIC ANTIGEN RECEPTORS AND LENTIVIRAL VECTORS IN THE 
TREATMENT OF CANCER  
The recent pilot study conducted by Dr. Carl June and his colleagues at UP 
involved three patients with chemotherapy-resistant CLL. Two of them had p53-
deficient CLL, a 17p deletion that usually indicates poor response to conventional 
treatment. Before enrollment in the study, all the patients underwent standard 
therapies, such as rituximab, fludarabine and bendamustine. Nevertheless, all had 
significant tumor burdens right before the trial, including bone marrow infiltration and 
lymphoadenopathy. One patient also had peripheral lymphocytosis.  
The lentiviral vector used, GeMCRIS 0607-793 (Figure 5), was produced by 
Lentigen Corp. using a three-plasmid approach. It contained the transgene CD-19-
BB- ! which coded for a second-generation chimeric antigen receptor (Kalos et al. 
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2011).  The receptor was comprised of the 
single-chain variable fragment (scFv) from 
the  human CD19-specific murine antibody 
(FMC63), a human CD8# hinge region, a 
human 4-1BB (CD137) co-stimulatory 
signaling domain, and a human CD3-! 
signaling domain (June et al. 2011). As 
previously mentioned, the inclusion of the 
4-1BB signaling domain considerably 
enhanced anti-tumor activity and in vivo 
persistence of CARs in preclinical trials. 
This effectiveness was also observed in the 
clinical trial.  
The patients’ cells were obtained via 
leukapheresis. Anti-CD3/CD28 mAB-
coated paramagnetic beads were used to 
positively select and activate T cells while 
remaining leukemic cells were depleted.  
GeMCRIS 0607-793, the lentiviral vector 
housing the transgene, was added to the 
culture and washed out three days later. 
The transduced cells were then allowed to 
expand for eight to ten days. Finally, the magnetic beads were removed by passing 
them through a magnetic field. The CART19 cells were collected, washed, 
concentrated, and cryopreserved in infusible medium (Kalos et al. 2011).   
PATIENTS’ RESPONSES 
One to four days preceding the infusion of tranduced T-cells, all the patients 
underwent a round of lymphodepleting chemotherapy.  Subsequently, each patient 
was infused intravenously with the transduced T cells over a three-day period as 
follows: 10%, 30%, and 60% of the dosage was infused on days one, two, and three, 
respectively. Patient UPN 03, the focus of this paper, began to have low-grade fevers 
associated with grade-2 fatigue two weeks after the infusion. Over the next few days, 
his temperature increased. Other symptoms, such as diarrhea, nausea, anorexia, and 
diaphoresis, were also observed. On day 22, he was diagnosed with tumor lysis 
syndrome, a metabolic complication that results when the kidneys are overburdened 
with a large load of destroyed tumor cells. The patient’s uric acid and lactate 
dehydrogenase levels were above normal at 10.6 mg/dL and 1130 U/L, respectively. A 
creatinine level of 2.6 mg/dL indicated acute kidney injury.  The patient was 
hospitalized and treated. His uric acid level returned to normal within 24 hours and 
the creatinine level within three days. He was discharged on the fourth day, and lactate 
dehydrogenase levels gradually decreased and returned to normal within a month.  
On day 23 after infusion of the CART19 cells, CLL was absent from the bone 
marrow (BM) of UPN 03. By day 28, adenopathy was not palpable, and on day 31, 
CT scanning showed its resolution. In 198 out of 200 cells examined, FISH testing was 
negative for the p53 deletion. Flow cytometry indicated B-cell aplasia and no residual 
CLL. Three months later, CT scanning showed sustained remission. In addition, at 
Figure 5: Lentiviral transfer vector construct 
used in the UP trial. The major functional 
elements of the transgene (represented by the 
sectional arrow labeled CD19BB !) are 
outlined in the bar at the bottom of Figure 5.  
Source: June et al. 2011 
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three and six months after infusion, studies of BM indicated no evidence of CLL as 
well as normal B cells (Figure 6). As of the publication of the study, remission has 
been sustained for ten months (June et al. 2011).   
Patient UPN 02 also developed fevers and was hospitalized after CART19 
infusion. Adenopathy was reduced somewhat, and p53 deficient CLL cells were 
eradicated from peripheral blood (PB). However, one month later, his BM was still 
infiltrated extensively with CLL cells. Thus, he had only sustained partial remission. !
Patient UPN 01 also developed symptoms upon infusion. No CLL cells were 
detected in his blood one and sixth months later. BM studies were performed one, 
three, and six months after infusion and indicated total absence of CLL cells. 
Adenopathy was resolved as observed by CT scans one and three months after 
infusion. He remained in remission for over ten months as of the publication of the 
study (Kalos et al. 2011).  
CART19 EFFECTOR-TO-CLL TARGET CELL RATIO 
In preclinical trials involving humanized mice, 2.2 x 107 CAR T cells were able 
to destroy tumors containing 1 x 109 cells (Kalos et al. 2011, as discussed in June et al. 
2009).  However, these calculations did not take into account in vivo expansion of the T 
cells. In the aforementioned UP trial, the three patients had their tumor loads 
estimated before infusion of the CAR T cells. This was done by calculating CLL cells 
in blood, bone marrow, and secondary lymphoid tissue. Patient UPN 03 had an 
estimated 8.8 x 1011 CLL cells in his bone marrow and 4.4 x 1011 CLL cells in 
secondary lymphoid tissue, totaling approximately 1.3 x 1012 tumor cells. His infusion 
contained only 1.4 x 107 CART19 cells. An astounding effector-to-target (E/T) ratio of 
1:93,000 resulted in complete elimination of CLL cells. The overwhelming 
effectiveness of the CART19 cells is most likely due, in part, to their in vivo expansion.  
The E/T ratios observed in patients UPN 01 and UPN 02 were 1:2200 and 1:1000, 
respectively (Kalos et al. 2011).  
SAFETY OF CART19 CELLS 
No long-term toxicity, other than B cell aplasia, was observed as a result of 
CART19 infusion. The patients did, however, develop transient febrile reactions and 
other short-term symptoms indicative of a serious immune response that coincided 
with tumor destruction (June et al. 2011). 
Figure 6: Bone marrow specimens of patient UPN 03. “The baseline specimen shows hypercellular bone 
marrow (60%) with trilineage hematopoiesis, infiltrated by predominantly interstitial aggregates of small, 
mature lymphocytes that account for 40% of total cellularity. The specimen obtained on day 23 shows 
residual lymphoid aggregates (10%) that were negative for chronic lymphoid leukemia (CLL), with a mixture 
of T cells and CD5-negative B cells. The specimen obtained 6 months after infusion shows trilineage 
hematopoiesis, without lymphoid aggregates and continued absence of CLL.” Source: June et al. 2001  
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CYTOKINES 
The patients’ immune responses were accompanied by sharp increases in 
cytokines. Peripheral blood and bone marrow samples were analyzed and significant 
increases in interleukin-6, (IL-6), IL-8, IL-10, and interferon-" (IFN- ") were 
observed in patients UPN 01 and 02. Levels of chemokines, such as CXCL9 and 
CXCL10, also rose. Cytokine and CART19 cell levels both peaked at the same time, 
coinciding with the patients’ clinical symptoms and eradication of tumor cells.  
The chimeric antigen receptor used in this trial contained a 4-1BB signaling 
domain as opposed to CD28. CARs containing a CD28 signaling domain are 
associated with increased levels of IL-2 and tumor necrosis factor-# both of which are 
undesirable. Previous studies have shown that high levels of IL-2 suppress CAR T 
cells, and TNF-# is associated with cytokine-storm effects. Levels of IL-2 and TNF-# 
did not rise in any of the patients (Kalos et al. 2011).  
IN VIVO EXPANSION, PERSISTANCE, AND BONE MARROW 
TRAFFICKING  
On the first day after infusion, real-time PCR detected expression of the anti-
CD19 CARs in patient UPN 03. The doubling time of CART19 cells was 
approximately 1.2 days. By day 21, a 3-log expansion of the cells was observed. 
CART19 cells comprised over 20% of circulating lymphocytes at peak levels, 
coinciding with the elevated levels of serum cytokines and the tumor lysis syndrome. 
Six months after infusion, CART19 levels were still significantly high, although they 
decreased by a factor of ten.  The elimination half-life of the cells was 31 days. 
CART19 cells were also detected in the bone marrow beginning on day 23 and 
remained there for at least six months. Their half-life in the BM was 34 days, slightly 
longer than those in circulation. Three months after treatment, no CD19 or normal B 
cells were detected (June et al. 2011).  Interestingly, none of the patients had an 
immune response targeting the CART19 cells even though they contained murine-
derived segments. This may be due to the patients’ severely compromised immune 
systems resulting from heavy pretreatment of CLL (Kalos et al. 2011).  
LONG-TERM EXPRESSION AND ESTABLISHMENT OF MEMORY 
In previous studies that have been conducted, CART cells have not been 
effective for prolonged periods of time. The long-term success of CART19 cells in the 
UP trial may be due to improved construction of the CAR. Several months after 
infusion, the values obtained by PCR for the prevalence of the CAR transgene closely 
matched those obtained by flow cytometry for the frequency of circulating CART19 
cells.  Blood and BM samples of UPN 03 that were analyzed by flow cytometry 169 
days after infusion indicated the presence of CART19 cells and complete absence of B 
cells. In all three patients, PCR indicated that CART19 cells persisted for at least four 
months. At 71 days after infusion, 5.7% of the T cells in the blood of patient UPN 01 
expressed CARs, and on day 286, 1.7% expressed CARs. Although small, these 
percentages indicate long-term expression of a CART19 population, possibly 
indicating long-term immunity too. 
Polychromatic flow cytometry was also performed to study the function and 
phenotype of CART19 cells in patient UPN 03. On day 56, CART19 CD8+ cells 
expressed an effector memory phenotype which is normally stimulated by prolonged 
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exposure to an antigen. By day 169, some of the CART19 CD4+ cells expressed a 
central memory phenotype, as indicated by CCR7 and CD127 expression, both of 
which are associated with memory T cells. B cell progenitors in the BM could ensure 
that CART19 cells maintain a memory population, thereby providing long-term 
immunity to CLL with the use of CART19 cells (June et al. 2011).  
CONCLUSION 
Decades of research in genetics, immunology, and molecular biology have 
culminated in the ability of medical scientists to treat patients with CLL with 
autologous T cells. In the UP trial of Dr. Carl June and his colleagues, two out of 
three patients enrolled in the study have reached total remission, and one achieved 
partial remission. The engineering of chimeric antigen receptors, the ability to use 
lentiviral vectors to transduce T cells to express them, and the in vivo expansion and 
persistence of these CAR cells all represent monumental breakthroughs that will, 
hopefully, be transposed to other areas of medicine as well.   
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